Candel Therapeutics Inc. (CADL)
CADL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2022-12-31, https://www.sec.gov/Archives/edgar/data/1841387/000095017024037637/0000950170-24-037637-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2022-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CADL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001841387 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2022
| Line | Value |
|---|---|
| Revenue | $125K |
| Net income | -$18.8M |
| Operating income | -$34.7M |
| Net margin | -15035.2% |
| Operating margin | -27777.6% |
| Revenue growth | 0.0% |
| Cash | $70.1M |
| Total assets | $77.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3646.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $203.1M cash; operating cash flow -$17.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 78,445,937 (2026-11-05); 54,898,303 a year earlier; 28,919,810 three years earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-11-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $3.0M, sold $3.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$21.9M | -$23.1M | $203.1M | $1.1M | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$38.9M | -$17.2M | $201.6M | $1.1M | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$8.9M | -$18.0M | $194.8M | $1.0M | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | Not filed | -$29.5M | -$10.6M | $119.7M | $1.0M | Needs four quarters | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | Not filed | -$11.3M | -$10.2M | $87.0M | $5.2M | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$4.8M | -$8.9M | $100.7M | $7.6M | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | $7.4M | -$8.6M | $92.2M | $10.1M | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | Not filed | -$14.1M | -$5.8M | $102.7M | $11.6M | Needs four quarters | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-11-12 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 423 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -29.1% |
| 1 month | -33.1% |
| 3 months | -47.5% |
| Year to date | +9.7% |
| 1 year | +34.5% |
| From 52-week high | -54.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| FENC | Fennec Pharmaceuticals Inc. | $12.76 | +9.81% | $450.5M |
| RGNX | REGENXBIO Inc. | $7.32 | -4.19% | $484.0M |
| TVGN | Tevogen Inc. | $6.22 | +3.67% | $422.2M |
| TECX | Tectonic Therapeutic Inc. | $20.98 | -0.76% | $418.5M |
| IRLA | IRulya Therapeutics Inc. | $37.36 | -6.13% | $405.0M |
| SLBT | SL Science Holding Limited | $0.7195 | -3.42% | $403.5M |
| ETRA | Electra Therapeutics Inc. | $8.31 | -6.00% | $522.4M |
| ENTX | Entera Bio Ltd. | $3.02 | -2.89% | $525.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier